Targeting brain metastases with ultrasmall theranostic nanoparticles, a first-in-human trial from an MRI perspective
Open accessThe DOI matches its Crossref record.
Abstract
Intravenously injected theranostic Gd-based nanoparticles enable targeting and MRI detection of brain metastases in patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Lammers, T. (2024) · Advanced Materials · doi:10.1002/adma.202312169 · Cited by 290
The blood–tumour barrier in cancer biology and therapy
Steeg, P. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00529-6 · Cited by 287
Yan, J., Wang, G., Xie, L., Tian, H., Li, J., Li, B., Sang, W., Li, W., Zhang, Z., & Dai, Y. (2022) · Advanced Materials · doi:10.1002/adma.202105783 · Cited by 253
Artificial intelligence aids in development of nanomedicines for cancer management
Tan, P., Chen, X., Zhang, H., Wei, Q., & Luo, K. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.01.005 · Cited by 246
Verry, C., Dufort, S., Villa, J., Gavard, M., Iriart, C., Grand, S., Charles, J., Chovelon, B., Cracowski, J.-L., Quesada, J.-L., et al. (2021) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2021.04.021 · Cited by 173
“162 Details of the contrast agent characteristics of AGuIX in this phase I trial have been previously published [20].”
BackgroundSelf-citationSun, H., Cai, H., Xu, C., Zhai, H., Lux, F., Xie, Y., Feng, L., Du, L., Liu, Y., Sun, X., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01654-9 · Cited by 86
Self-citationThivat, E., Casile, M., Moreau, J., Molnar, I., Dufort, S., Seddik, K., Le Duc, G., De Beaumont, O., Loeffler, M., Durando, X., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-10829-y · Cited by 76
“Moreover, this clinical trial also demonstrated (i) the selective accumulation of AGuIX in brain metastases from different types of primary tumors due to the EPR effect, with a persistence in the tumor lasting few days after injection, (ii) a dose-correlated uptake of AGuIX in brain metastases, (iii) a dose-correlated…”
BackgroundSelf-citationBilynsky, C., Millot, N., & Papa, A. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10256 · Cited by 52
“Finally, AGuIX MRI SE was still detected a week post-injection, which denotes a key improvement in local retention, in comparison to existing Gd-based contrast agents.(131) This initial success led to the NANORAD2 phase II trial (NCT03818386) that is currently recruiting patients and consists of 3 100 mg/kg AGuIX IV i…”
MethodResultZhang, J., Lu, L., Zhang, W., Miao, Y., Du, H., Xia, H., Tao, Z., Du, Z., Tang, Y., & Fang, Q. (2025) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2024.114374 · Cited by 7
Atkinson, J., Chopin, J., Bezak, E., Le, H., & Kempson, I. (2025) · ChemPhysChem · doi:10.1002/cphc.202400764 · Cited by 5
Metadata
- Authors
- Verry, C., Dufort, S., Lemasson, B., Grand, S., Pietras, J., Troprès, I., Crémillieux, Y., Lux, F., Mériaux, S., Larrat, B., Balosso, J., Le Duc, G., Barbier, E. L., & Tillement, O.
- Venue
- Science Advances
- Published
- 2020-07-17
- Volume
- 6
- Issue
- 29
- Pages
- eaay5279-eaay5279
- ISSN
- 2375-2548 (ISSN-L)
- OpenAlex
- W3042444813
- Cited by
- 145
- References
- 0
- FWCI
- 8.87
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.